Bombay High Court: Cipla FDA Licenses Cancellation Withdrawn After Reprimand

• The Bombay High Court reprimanded the Maharashtra Food and Drug Administration (FDA) for the "high-handed" cancellation of Cipla's wholesale drug licenses.
• The court criticized the FDA for issuing a hearing notice on a state holiday when its office was closed, deeming it unfair and non-transparent.
• Cipla's Wadki, Pune distribution hub, affected by the cancellation, serves 180 customers and distributes over 430,000 medicine units monthly across Maharashtra.
• Following the court's strong remarks, the State government agreed to immediately withdraw the cancellation order.
• A fresh notice will be served to Cipla before September 4, ensuring proper procedural adherence.

This case reinforces that even well-intentioned regulatory efforts must not bypass fundamental principles of natural justice, such as providing adequate and proper notice.

The Bombay High Court recently intervened in a dispute involving Cipla Limited, strongly criticizing the Maharashtra Food and Drug Administration (FDA) for its "high-handed" approach in cancelling wholesale drug sale licenses. This significant ruling, stemming from the case of Cipla Limited v. State of Maharashtra & Ors, saw a division bench comprising Acting Chief Justice Ravindra V Ghuge and Justice Gautam A Ankhad reprimand the regulatory body for what they deemed hasty and inappropriate conduct.

Cipla had sought judicial recourse after the FDA revoked licenses essential for its primary distribution hub located in Wadki, Pune. The pharmaceutical company underscored the critical role of this facility, which services approximately 180 customers and is responsible for distributing over 430,000 units of medicines across Maharashtra each month. The abrupt cancellation threatened to disrupt a vital supply chain for a substantial volume of pharmaceutical products.

A key point of contention highlighted by the Court was the procedural irregularity surrounding the FDA's actions. Chief Justice Ghuge specifically questioned the fairness and transparency of issuing a hearing notice on August 26, a state holiday, when the FDA's offices were closed. The Chief Justice remarked on the FDA's tendency to act "overboard," noting that this was not an isolated incident despite acknowledging the agency's commendable work.

The Bombay High Court's strong remarks prompted an immediate response from the State government. Following the judicial reprimand, the government pleader informed the bench that the cancellation order affecting Cipla's wholesale drug licenses would be withdrawn without delay. Furthermore, the authority committed to serving a fresh notice to the company before September 4, ensuring proper procedural adherence moving forward.

This swift resolution underscores the judiciary's emphasis on due process, even when regulatory bodies are performing their duties. The FDA's initial actions were reportedly based on inspections conducted at Cipla's Wadki facility during June and August. However, the court's intervention focused less on the substantive findings of these inspections and more on the procedural flaws in the subsequent license cancellation. The ruling effectively halted the FDA's "high-handed cancellation" and mandated a re-evaluation under proper legal protocols.

The Bombay High Court's decision serves as a crucial reminder of the importance of procedural fairness and transparency in regulatory actions, particularly for bodies like the Maharashtra Food and Drug Administration. The court's reprimand against the FDA for its "overboard" conduct sets a precedent that regulatory authorities, while tasked with vital public safety roles, must operate strictly within the bounds of law and due process. This case reinforces that even well-intentioned regulatory efforts must not bypass fundamental principles of natural justice, such as providing adequate and proper notice.

This ruling has significant implications for entities subject to regulatory oversight, offering a clear signal that arbitrary or procedurally flawed decisions by government agencies can be successfully challenged. The incident involving Cipla's wholesale drug licenses in Wadki highlights the judiciary's role in safeguarding businesses from actions that lack appropriate legal foundation or procedural integrity. It underscores the need for regulatory bodies to ensure that their enforcement mechanisms are not only effective but also scrupulously fair and transparent, thereby preventing future instances of "FDA high-handed cancellation."

This ruling reinforces the importance of due process and fair hearing in regulatory actions, providing a precedent for challenging 'high-handed' or procedurally flawed decisions by bodies like the FDA. Lawyers and compliance officers should note this when advising clients on regulatory compliance or when facing arbitrary actions from government agencies.

Source: Original reporting via legal news outlets